SCIENCE THROUGH NETWORKING

News

In this section, is reported the full ATMP news database, sorted by area of interest

Mustang Bio, an american biotech company, has announced that its therapy MB-108 has achieved the orphan drug status from FDA, which provides Mustang with additional market exclusivity and financial incentives to advance its product, an oncolytic virus developed to treat glioma, an aggressive form of brain cancer

Date: May 16, 2019

During the annual meeting of Assobiotech-Federchimica held in Rome Riccardo Palmisano, CEO of MolMed, has been confirmed President of Assobiotec, national association for the biotechnology development and that represents about 130 biotech companies. Also in the event, Professor Franco Locatelli, Chief of Paediatric Haematology/Oncology and Transfusion Medicine of Bambino Gesù children’s Hospital and CAR-T pioneer, received the Assobiotec award 2019

Date: May 16, 2019

Sarah Cannon Research Institute in Nashville and MD Anderson Cancer Center in Houston have opened a clinical trial involving TC-102, a novel T-cell therapy of TCR2 Therapeutics for patients with mesothelioma. Until recently, T-cell therapy hae been effective only when treating blood cancers such as lymphoma or leukemia and not against solid tumors, but advances such as TC-210 are changing this perception

Date: May 16, 2019

Axovant, a company developing innovative gene therapy, has announced dosing of the first patient involved in a clinical study of AXO-AAV-GM1, investigational gene therapy against GM1 gangliosidosis, a rare pediatric disease caused by a gene mutation that leads to impaired production of the beta-galactosidase. The therapy is based on a viral vector that delivers a functional copy of the GLB1 gene, with the goal of restoring β-galactosidase

Date: May 16, 2019

Homology Medicines, an American genetic medicines company, has announced the Fast Track designation from FDA for HMI-102, single administration gene therapy for the treatment of adults with phenylketonuria. This designation  is intended to facilitate the therapy development and fasten up access for patients with unmet medical need.

Date: May 14, 2019

Humanitas Research Hospital and the Institute for Genetic and Biomedical Research are studying the chromosome transplant like a viable solution against some genomic abnormalities. The study, published on Stem Cells, is based on CRISPR-Cas9 technology and special viral vectors, used for intact chromosomes transplant in cells with small gene alterations involved in various disease, like Duchenne muscular dystrophy and chronic granulomatous disease.

Date: May 14, 2019

Poseida Therapeutics, an american biopharmaceutical company, today announced FDA has granted orphan drug designation to P-BCMA-101 for the treatment of relapsed and/or refractory multiple myeloma. The therapy is developed with piggyBac technology, that allows for CAR-T products with a high percentage of stem cell memory T cells, leading to therapies with improved efficacy and potenially greater durability combined with lower toxicity than earlier generation CAR-T

Date: May 13, 2019

The ongoing Phase 2b clinical trial is designed to determine the safety and kinetics of a single intravenous infusion of AMT-061 in Hemophilia B patients. The data were presented at the Hemostasis & Thrombosis Research Society Scientific Symposium, and showed clinically significant increase in Factor IX activity in all three patients up to six months after a single dose

Date: May 13, 2019

The program will provide in six working groups involved in as many sub-project, from the new cancer-targets discovery to the intellectual property and patent coverage of the medicinal products. At the moment €10 millions are available for “State CAR-T”, useful for the preclinical phase, but not for the clinical trials development

Date: May 9, 2019

The experiment with an italian leadership, published on Nature, achieves positive results in tissue damages repair, after myocardial infarction, in pigs. Differently from traditional gene therapy, the genetic material transferred in heart stimulates cell regeneration by protein synthesis inhibition and, according to the research co-ordinator, human clinical trial could be concluded within 5 years

Date: May 9, 2019

Phase 1 clinical data show that VY-AADC, investigational gene therapy co-developed by Voyager and Neurocrine Biosciences, is able to improve motor function and decrease the need of pharmaceutical therapy in advanced Parkinson’s patients. The drug, directly administered in striatum, aims to enable the neurons of the putamen to produce the AADC enzyme to convert levodopa into dopamine

Date: May 8, 2019

Mustang Bio, american biopharmaceutical company focused  focused on translating today’s medical breakthroughs in cell and gene therapie  has announced that   City of Hope, a renowned independent cancer research and treatment center, has began enorlling patients for a phase 1 clinical trial focused on a new CAR-T therapy anti-CS1, protein expressed in nearly all multiple myeloma patients

Date: May 8, 2019

Verve Therapeutics, american biotech Company, tries to modify the genome to reproduce natural gene mutations, that have proven protective effects against heart attacks. The project purpose is to replace the current treatment and prevention therapies with a single administration therapy

Date: May 8, 2019

The Cipe resolution proposal is ready for the allotment of sanitary construction resources allocated by the Budget Law 2019, amounting to €4.695 billions, that has already achieved the Ministry of Economy green light and it will be examined in the next State-Regions Conference. Highlighted the allocation of €60 millions for the development of 6 CAR-T centers of excellence

Date: May 8, 2019

Gene therapy used for treat children with severe combined immunodeficiency and myotubular myopathy X-linked, with positive results respectively on the restoration of immune system and the production of myotubularin with the consequent partial recovery of muscular and breathing capacity

Date: May 7, 2019

The program will provide in six working groups involved in as many sub-project, from the new cancer-targets discovery to the intellectual property and patent coverage of the medicinal products. At the moment €10 millions are available for “State CAR-T”, useful for the preclinical phase, but not for the clinical trials development

Date: May 6, 2019

Novartis presented the results of clinical trials about Zolgensma, whose approval is expected at the end of May; the drug developed by AveXis, recently acquired by the swiss Company, showed relevant effects on infants with SMA1 and it has been tested on the others disease forms, with encouraging results

Date: May 6, 2019

The phase 1 trial results, published on Nature Medicine, show a potent and durable antilymphoma response of a second generation anti CD19 CAR-T therapy, without causing neurotoxicity or severe cytokine release syndrome

Date: May 6, 2019

Daniel O’Day announces that Kite Pharma, CAR-T focused Company, will be an independent business unit of Gilead, that has acquired it in 2017 for $11.9 billions, to promote efficient and successful activities, helping it to maintain a leadership position in cell therapies

Date: May 5, 2019

 Public institutions support to universities, access processes and to the pharmaceutical industry becomes fundamental for the articulated production process of specific patient solutions offered by advanced therapy

Date: May 3, 2019
Page 1 of 21

With the unconditional support of

We use cookies, just to track visits to our website, we store no personal details